WO1997035557A1 - Composition topique pour soigner la peau - Google Patents

Composition topique pour soigner la peau Download PDF

Info

Publication number
WO1997035557A1
WO1997035557A1 PCT/JP1997/000880 JP9700880W WO9735557A1 WO 1997035557 A1 WO1997035557 A1 WO 1997035557A1 JP 9700880 W JP9700880 W JP 9700880W WO 9735557 A1 WO9735557 A1 WO 9735557A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell adhesion
skin
inhibiting substance
adhesion inhibiting
substance
Prior art date
Application number
PCT/JP1997/000880
Other languages
English (en)
Inventor
Takatoshi Murase
Tadashi Hase
Yusuke Shibuya
Yoshinori Nishizawa
Ichiro Tokimitsu
Original Assignee
Kao Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP6607696A external-priority patent/JPH09255546A/ja
Priority claimed from JP15528096A external-priority patent/JPH107556A/ja
Application filed by Kao Corporation filed Critical Kao Corporation
Publication of WO1997035557A1 publication Critical patent/WO1997035557A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0212—Face masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755—Gymnosperms [Coniferophyta]
    • A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Definitions

  • the present invention relates to an external skin-care composition which is useful in
  • the skin is anatomically divided into epidermis, dermis and subcutaneous tissue in order from the surface thereof.
  • the epidermis is composed mainly of keratinocytes into
  • stratum basale which pigment cells (melanocytes), Langerhans' cells and the like are mixed.
  • stratum basale stratum spinosum, stratum granulosum and
  • stratum comeum under an optical microscope.
  • the keratinocytes divide at an almost constant rate in the stratum basale. which is the lowest stratum, and are successively pushed up from
  • the stratum basale (keratinization).
  • the keratinocytes gradually flatten during this process
  • fibroblasts and mast cells exist in the dermis in a form where they
  • extracellular matrix proteins called the extracellular matrix, such as collagen and elastin
  • sensation and may have an increase in spots (pigmentation), disorder of skin texture or skm
  • the usual skin irritation and itch may be caused by various factors, for example,
  • Antihistam es and steroids heretofore m use as drugs, and antipyretic-analgesic agents such
  • substance P antagonists are effective for allergic skin (Japanese Patent Application Laid-Open
  • the dermis situated under the epidermis is also affected by endogenous factors and
  • composition useful in preventing and improving peeling, pachymenia, skin roughness, disorder of skin texture, pigmentation, degeneration or destmction of dermal components, or
  • lymphocyte adhesion inhibiting substance which prevents the lymphocytes from
  • angioendothelial cells can effectively prevent the formation of spots on the skin, skin
  • an external skin-care composition for preventing and improving peeling, pachymenia, skin roughness, disorder of skin texture, pigmentation, degeneration or destruction of dermal components, or itch, which
  • angioendothelial cells comprises a substance inhibiting cell adhesion between angioendothelial cells and lymphocytes.
  • a method of preventing and improving peeling, pachymenia, skin roughness, disorder of skin texture, pigmentation, degeneration or destmction of dermal components, or itch by applying a composition
  • lymphocytes to the skin to be treated.
  • the leukocytes and angioendothelial cells adhere to each other through specific cell adhesion
  • the inflammation is a local response to a lesion of a vital tissue.
  • tissue is damaged by physical irritation such as
  • lymphocytes and the infiltration of the lymphocytes participate in various aspects
  • lymphocytes used in the present invention is not limited to any special substance.
  • lymphocytes used in the present invention is not limited to any special substance.
  • nonprotein substances are particularly preferred in view of percutaneous absorption.
  • benzoic acid anilide derivatives gallic acid derivatives, benzene derivatives and
  • cell adhesion inhibiting substance may include Thujopsis dolabrata (ASUNARO) or extracts therefrom, lignans and morgins.
  • Thujopsis dolabrata is a genus endemic to Japan and an evergreen tree ranging in
  • a dry ground product composed mainly ol leaves, twigs and
  • Thujopsis dolabrata the like (hereinafter referred to as "stock") of Thujopsis dolabrata may be used as it is It is
  • Thujopsis dolabrata by grinding mainly leaves, twigs and the like of Thujopsis dolabrata in a dried or und ⁇ ed
  • the extract from Thujopsis dolabrata means an extract with any of various
  • the extract with the solvent is obtained by extracting the stock of Thujopsis dolabrata
  • an organic solvent a hydrocarbon solvent such as petroleum ether, n-hexane cyclohexane, toluene or benzene, a halogenated hydrocarbon such as dichloromethane,
  • chloroform or carbon tetrachloride an ether solvent such as diethyl ether, an ester solvent such as ethyl acetate, a ketone such as acetone, a basic solvent such as pyridine, a
  • monohydric or polyhydric alcohol solvent such as butanol. propanol. ethanol, methanol,
  • polyethylene glycol polyethylene glycol, propylene glycol or butylene glycol, or the like), an aqueous alcohol or
  • a method for extracting the stock of Thujopsis dolabrata may be mentioned a method in which 100 g of a dry ground product of Thujopsis
  • dolabrata are immersed m 1 liter of ethanol to conduct extraction for 7 days while sometimes
  • the above extract mav be used as an active ingredient for the cell adhesion inhibiting agent according to the present invention or other medicines in the form of a solution as extracted, it may be used in the form of a highly-active fraction by concentrating
  • Thujopsis dolabrata or the extract therefrom may be prepared into powder or paste as
  • lignans include compounds represented by the following general formula (1 ):
  • R 1 . R : . R 3 and R 4 are the same or different from one another and individually represent a hydrogen atom, or a hydroxyl, alkyl or alkoxyl group.
  • the alkyl group preferably has 1 -10 carbon atoms.
  • the alkoxyl group is
  • n-propyloxy isopropyloxy, n-butyloxy, sec-butyloxy, tert-butyloxy, pentyloxy,
  • R 1 is a hydrogen
  • R : , R 3 and R 4 are hydroxyl or methoxy groups are particularly preferred.
  • Such lignans (1 ) can be extracted from, for example, Thujopsis dolabrata (mainly
  • the extraction is performed by extracting Thujopsis dolabrata or
  • glycol butylene glycol or the like
  • aqueous alcohol or the like at usually about 3-70°C.
  • dolabrata may be mentioned a method in which 100 g of a dry ground product of Thujopsis
  • dolabrata are immersed in 1 liter of ethanol to conduct extraction for 7 days with occasional
  • benzene as a eluting solvent and a hydrophilic polymer such as AMBERLITE XAD-2,
  • phase silica gel, silica gel, or cellulose as a support to fractionate the intended component
  • the product may be purified by recrystallization making use of a suitable solvent
  • the morgins include compounds represented by the following general formula (2):
  • R D and R are the same or different from each other and individually represent a hydroxyl or alkoxyl group.
  • the alkoxyl group is preferably linear or branched and has 1-6
  • Such morgins (2) can be extracted from, for example, a madder.
  • the extraction is
  • a madder performed by first extracting a madder with a solvent such as diethyl ether, ethyl acetate, acetone, methanol, ethanol, hexane or water. The solvent is then distilled from the resultant
  • ⁇ may be purified by recrystallization making use of a suitable solvent such as benzene, ether, hexane, acetone, methanol, ethanol or water in some cases.
  • a suitable solvent such as benzene, ether, hexane, acetone, methanol, ethanol or water in some cases.
  • the amount of such a cell adhesion inhibiting substance to be used is preferably 0.000001 -10 wt.%, particulariy preferably 0.0001-1 wt.% based on the weight of the external
  • a water-absorbing gelling agent for example, a water-absorbing gelling agent, a lipophilic gelling agent, a water-absorbing active ingredient, a lipophilic active ingredient, an antiseptic, an antioxidant, a solvent, a perfume
  • an amount of these additives to be inco ⁇ orated may be an amount commonly used in the classical external skin-care compositions and may
  • oils which may be used include mineral oils (vaseline and the like),
  • oils vegetable oils (sunflower oil and the like), animal oils, synthetic oils (pruserin oil and the like), siiicone-containing oils and fluorinated oils (perfluoropolyether and the like). These oils may be used in combination with fatty alcohols and fatty acids (stearic acid and the like)
  • emulsifiers examples include glycerol stearate,
  • POLYSORBATE 60 and a mixture of PEG-6/PEG-32/glycol stearate product of Gattefosse Co.; trade name: TEFOSE.
  • the solvent include lower alcohols with ethanol and
  • lipophilic gelling agent examples include modified clay, metal salts of fatty acids and hydrophobic silica.
  • water-absorbing active ingredient examples include proteins, hydrolyzates of
  • lipophilic active ingredient examples include retinol and
  • agents selected from antibacterial agents, antifungal agents, anti-inflammatory agents, and/or anti-inflammatory agents are more agents selected from antibacterial agents, antifungal agents, anti-inflammatory agents, and/or anti-inflammatory agents.
  • antipruritics antiviral agents
  • keratolytic agents free radical scavengers
  • antioxidants antioxidants
  • antisebaceous agents antidandruff agents, antipimple agents and humectants.
  • antibacterial agents include antibiotics of the clindamycin phosphate, erythromycine and tetracydine types, and the like.
  • the antifungal agents include imidazole compounds such as
  • amphotericin allylamines such as terbinafine and octopirox; and the like.
  • inflammatory agents include steroids such as hydrocortisone and betamethasone; ibuprofen and salts thereof, acetylsalicylic acid, acetoaminophen, glycyrrhetinic acid, and the like.
  • steroids such as hydrocortisone and betamethasone
  • ibuprofen and salts thereof acetylsalicylic acid, acetoaminophen, glycyrrhetinic acid, and the like.
  • antipruritics include thenaldine, trimeprazine, cyproheptadine and the like.
  • the antiviral agents include acyclovir and the like.
  • the keratolytic agents include -hydroxycarboxylic acids and salts thereof, ⁇ -
  • esters hydroxy acids such as glycolic acid, lactic acid, salicylic acid and citric acid, fruit
  • the free radical scavengers include ⁇ -
  • the antisebaceous agents include progesterones and the like.
  • the anti dandruff agents include progesterones and the like.
  • the antipimple agents include retinoic acid,
  • the humectants include natural and synthetic ceramides,
  • hyaluronic acid cholesterol and salt thereof, collagens, and the like.
  • the external skin-care composition according to the present invention may be any organic skin-care composition according to the present invention.
  • Examples of the forms of the external skin-care composition include aqueous solutions or aqueous alcohol solutions such as lotions; liquid or semiliquid emulsions of the water-in-oil
  • each emulsion is preferably 5-80 wt.%, particularly preferably 5-50 wt.% based on the weight of the external skin-care composition according to the present invention.
  • the external skin-care composition according to the present invention can be any organic skin-care composition according to the present invention.
  • liquid foundation cleansing lotion, skin care body lotion, sunscreen lotion, skin care lotion, gel or foam as necessary for the application intended.
  • Thujopsis dolabrata a rnixture of leaves and twigs
  • Thujopsis dolabrata a mixture of leaves and twigs
  • a dry ground product (180 g) of Thujopsis dolabrata was immersed in 1 liter of
  • Test Example 1 Adhesion inhibiting test between leukocvtes and angioendothelial cells
  • test substance was added to human angioendothelial cells turned confluent on a
  • human IL-1 ⁇ was added so as to give a final concentration of 2.5 ng/ml. followed by culture
  • Thujopsis dolabrata extracts tested were found to have excellent inhibitory activity against cell adhesion between the leukocytes and the angioendothelial cells
  • Test Example 2 Toxicity test against angioendothelial cell (cell form. DNA synthesis ⁇
  • test substance by means of a liquid scintillation counter.
  • concentration of the test substance was controlled to 0.0001 wt.%.
  • Test Example 3 Adhesion inhibiting test between leukocvtes and angioendothelial cells
  • test substance was added to human angioendothelial cells turned confluent on a
  • Test Example 4 Toxicity test against angioendothelial cell (protein s y nthesis)
  • test substance 4 hours in a 24-hour culture after adding a test substance by means of a liquid scintillation i counter.
  • concentration of the test substance was controlled to 10 nM.
  • Test Formula (1) Inhibition Inhibition substance rate of rate of leukocyte protein
  • Test Example 5 Adhesion inhibiting test between leukocvtes and angioendothelial cells
  • test substance was added to human angioendothelial cells turned confluent on a 96-well culture plate so as to give a final concentration of 10 ⁇ M. After 18 hours, human IL-
  • Test Example 6 Toxicity test against angioendothelial cell (cell form. DNA synthesis
  • Test Formula (2) Inhibition Inhibition Mo ⁇ hological substance rate of rate of change of leukocyte DNA angioendo ⁇
  • a cell adhesion inhibiting substance 100 mM; 10 ⁇ l was applied to 1 cm 2 of each of their backs. After 2 hours, a seal for a patch
  • epidermis was expressed in terms of actual measurements, while the degree of peeling was visually evaluated by relative comparison and ranked in 4 grades by which the state of a
  • Test Example 7 Effect of cell adhesion inhibiting substance on disorder of skin texture
  • a cell adhesion inhibiting substance (0.1 %; 15 ⁇ l ) was applied to 1 cm 2 of a human
  • Test Example 8 Effect of cell adhesion inhibiting substance on itch
  • a cell adhesion inhibiting substance (100 mM; 15 ⁇ l ) was applied to the backs of
  • mice Balb/c mice. After 2 hours, a histamine solution was intracutaneously injected into the mice.
  • mice were recorded over 1 hour by a video camera.
  • mice were scratching their sites dosed with histamine was counted from the video image to evaluate the effect on itch.
  • the results are shown in Table 7.
  • each back was divided into 8 portions each having an area of 1.5 cm 2 .
  • the back was
  • erythema dose MED
  • UVB erythema dose
  • the evaluation was performed by conducting measurement by means of a calorimeter
  • Test Example 10 Effect of cell adhesion inhibiting substance on destmction of dermal components
  • MED minimal erythema dose
  • Example 1 Skin lotion
  • Example 7 Cream (oil-in-water type emulsion)
  • Liquid component (Waxes, oils and esters) 1 1 5
  • Carboxyvinyl polymer (CARBOPOL 940, 0.2
  • Silicone composition (KSG-17, product 5.0
  • Example 12 Cosmetic emulsion
  • Polyethylene glycol 1500 2.0 Polyoxyethykne methylglucoside (20 EO) 1 . 5
  • Carboxyvinyl polymer (CARBOPOL 940, 0.2
  • Methylpolysiloxane (KF96A-500cs, product 2.0 of Shin-Etsu Chemical Co., Ltd.)
  • the external skin-care compositions according to the present invention are useful for centuries.

Abstract

L'invention concerne une composition topique pour soigner la peau et, en particulier pour empêcher ou maîtriser la desquamation, prévenir la pachydermie, les rugosités et autres anomalies de la texture de la peau, l'apparition de pigmentations ou la dégénérescence/destruction de composants dermiques, ainsi que les irritations. Cette composition contient une substance inhibant l'adhérence cellulaire entre les cellules angioendothéliales et les lymphocytes. La composition topique pour soigner la peau est utile contre toute une variété d'affections de la peau.
PCT/JP1997/000880 1996-03-22 1997-03-18 Composition topique pour soigner la peau WO1997035557A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP8/66078 1996-03-22
JP6607696A JPH09255546A (ja) 1996-03-22 1996-03-22 皮膚外用剤
JP8/66076 1996-03-22
JP6607896 1996-03-22
JP8/155280 1996-06-17
JP15528196 1996-06-17
JP15528096A JPH107556A (ja) 1996-06-17 1996-06-17 細胞接着抑制剤
JP8/155281 1996-06-17

Publications (1)

Publication Number Publication Date
WO1997035557A1 true WO1997035557A1 (fr) 1997-10-02

Family

ID=27464658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/000880 WO1997035557A1 (fr) 1996-03-22 1997-03-18 Composition topique pour soigner la peau

Country Status (1)

Country Link
WO (1) WO1997035557A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070433A1 (fr) * 2004-01-22 2005-08-04 Arachnova Therapeutics Ltd. Utilisation de la pentoxifylline pour la prevention ou le traitement des ulceres
WO2011045150A2 (fr) * 2009-10-12 2011-04-21 Unilever Nv Composition d'hygiène personnelle
WO2013161821A1 (fr) * 2012-04-24 2013-10-31 花王株式会社 Accélérateur de la réactivité au prgc
CN103965209A (zh) * 2014-05-15 2014-08-06 中国药科大学 去氧鬼臼毒素的新晶型及其制备方法
US9255239B1 (en) 2014-12-30 2016-02-09 Ivanhoe Industries, Inc. Formulation for corn oil recovery and method of use thereof
US9399750B1 (en) 2015-06-22 2016-07-26 Ivanhoe Industries, Inc. Formulation for corn oil recovery and method of use thereof
US9738850B1 (en) 2016-04-11 2017-08-22 Ivanhoe Industries Use of alkoxylyated mono- and diglycerides for corn oil recovery

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833732A (en) * 1973-05-24 1974-09-03 Miles Lab Method of treating inflammation utilizing alkyl esters of gallic acid
JPS62192307A (ja) * 1986-02-18 1987-08-22 Kanebo Ltd 皮膚化粧料
JPS63150208A (ja) * 1986-12-12 1988-06-22 Shiseido Co Ltd 皮膚外用剤
WO1991003252A1 (fr) * 1989-09-01 1991-03-21 Fred Hutchinson Cancer Research Center Inhibition de l'adhesion de lymphocytes sur l'endothelium vasculaire au moyen d'une nouvelle interaction entre le recepteur matriciel extra-cellulaire et son ligand
US5200429A (en) * 1990-09-28 1993-04-06 Takasago International Corporation Acne vulgaris treating
WO1993010796A1 (fr) * 1991-11-27 1993-06-10 Glycomed, Inc. Derives de lactose et de lactosamine a substitution utilises comme inhibiteurs d'adhesion cellulaire
DE4230186A1 (de) * 1992-09-09 1994-03-10 G N Pharm Arzneimittel Gmbh Verfahren zur Isolierung von Podophyllotoxin und/oder mindestens eines Podophyllotoxin-Derivats, sowie eine pharmazeutische Zubereitung, enthaltend mindestens ein Podophyllotoxin-Derivat
JPH07277939A (ja) * 1994-04-05 1995-10-24 Dowa Mining Co Ltd 皮膚外用剤
JPH08183722A (ja) * 1994-12-28 1996-07-16 Kao Corp 老化防止用皮膚化粧料
JPH08337537A (ja) * 1995-06-15 1996-12-24 Kao Corp 細胞間接着阻害ペプチド

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833732A (en) * 1973-05-24 1974-09-03 Miles Lab Method of treating inflammation utilizing alkyl esters of gallic acid
JPS62192307A (ja) * 1986-02-18 1987-08-22 Kanebo Ltd 皮膚化粧料
JPS63150208A (ja) * 1986-12-12 1988-06-22 Shiseido Co Ltd 皮膚外用剤
WO1991003252A1 (fr) * 1989-09-01 1991-03-21 Fred Hutchinson Cancer Research Center Inhibition de l'adhesion de lymphocytes sur l'endothelium vasculaire au moyen d'une nouvelle interaction entre le recepteur matriciel extra-cellulaire et son ligand
US5200429A (en) * 1990-09-28 1993-04-06 Takasago International Corporation Acne vulgaris treating
WO1993010796A1 (fr) * 1991-11-27 1993-06-10 Glycomed, Inc. Derives de lactose et de lactosamine a substitution utilises comme inhibiteurs d'adhesion cellulaire
DE4230186A1 (de) * 1992-09-09 1994-03-10 G N Pharm Arzneimittel Gmbh Verfahren zur Isolierung von Podophyllotoxin und/oder mindestens eines Podophyllotoxin-Derivats, sowie eine pharmazeutische Zubereitung, enthaltend mindestens ein Podophyllotoxin-Derivat
JPH07277939A (ja) * 1994-04-05 1995-10-24 Dowa Mining Co Ltd 皮膚外用剤
JPH08183722A (ja) * 1994-12-28 1996-07-16 Kao Corp 老化防止用皮膚化粧料
JPH08337537A (ja) * 1995-06-15 1996-12-24 Kao Corp 細胞間接着阻害ペプチド

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 107, no. 24, 14 December 1987, Columbus, Ohio, US; abstract no. 223073, XP002036599 *
DATABASE WPI Section Ch Week 8831, Derwent World Patents Index; Class B04, AN 88-215482, XP002036602 *
DATABASE WPI Section Ch Week 9551, Derwent World Patents Index; Class B05, AN 95-400871, XP002036603 *
DATABASE WPI Section Ch Week 9638, Derwent World Patents Index; Class D21, AN 96-379244, XP002036601 *
DATABASE WPI Section Ch Week 9710, Derwent World Patents Index; Class B04, AN 97-103659, XP002036600 *
I. BRUYNZEEL ET AL: "Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells", ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 289, 1997, BERLIN, pages 189 - 193, XP002037153 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070433A1 (fr) * 2004-01-22 2005-08-04 Arachnova Therapeutics Ltd. Utilisation de la pentoxifylline pour la prevention ou le traitement des ulceres
WO2011045150A2 (fr) * 2009-10-12 2011-04-21 Unilever Nv Composition d'hygiène personnelle
WO2011045150A3 (fr) * 2009-10-12 2011-11-03 Unilever Nv Composition d'hygiène personnelle
WO2013161821A1 (fr) * 2012-04-24 2013-10-31 花王株式会社 Accélérateur de la réactivité au prgc
JP2013227234A (ja) * 2012-04-24 2013-11-07 Kao Corp Ｃｇｒｐ応答性促進剤
RU2651766C2 (ru) * 2012-04-24 2018-04-23 Као Корпорейшн Стимулятор чувствительности к cgrp
CN103965209A (zh) * 2014-05-15 2014-08-06 中国药科大学 去氧鬼臼毒素的新晶型及其制备方法
CN105017274A (zh) * 2014-05-15 2015-11-04 中国药科大学 去氧鬼臼毒素的新晶型及其制备方法
CN105017274B (zh) * 2014-05-15 2017-01-18 中国药科大学 去氧鬼臼毒素的晶型及其制备方法
US9255239B1 (en) 2014-12-30 2016-02-09 Ivanhoe Industries, Inc. Formulation for corn oil recovery and method of use thereof
US9399750B1 (en) 2015-06-22 2016-07-26 Ivanhoe Industries, Inc. Formulation for corn oil recovery and method of use thereof
US9738850B1 (en) 2016-04-11 2017-08-22 Ivanhoe Industries Use of alkoxylyated mono- and diglycerides for corn oil recovery

Similar Documents

Publication Publication Date Title
US11752168B2 (en) Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats
KR100879558B1 (ko) 디벤조­파라­디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제
US20070254052A1 (en) Substances capable of potentiating laminin 5 productivity in epidermal cells and their use
KR101663946B1 (ko) 인삼꽃 흑효모 발효를 통한 진세노사이드 Rg3 강화 및 이를 유효성분으로 함유하는 화장료 조성물
WO1997035618A1 (fr) Preparation dermatologique
KR100361433B1 (ko) 인삼추출물을함유하는피부노화방지용화장료조성물
WO1997035557A1 (fr) Composition topique pour soigner la peau
KR20090007235A (ko) 오돈텔라 아우리타의 친지성 추출물의 피부 재구조화를위한 용도, 사용되는 조성물 및 상기 추출물을 사용하는화장 방법
KR101208013B1 (ko) 참바늘버섯 균사체 추출물을 함유하는 피부 외용제 조성물
KR100429590B1 (ko) 감태 추출물을 함유하는 주름개선 화장료 조성물
US8217074B2 (en) Use of sargachromenol
JPH09255546A (ja) 皮膚外用剤
KR100424726B1 (ko) 안정화시킨 비타민 c와 파이토스핑고신을 함유하는 피부보호화장료 조성물
KR101521239B1 (ko) 황금 붉은덕다리버섯 발효액을 유효성분으로 함유하는 피부 노화 방지 및 피부 주름 개선용 화장료 조성물
KR100695996B1 (ko) 자연산 상황버섯 추출물 함유 니오좀 및 이를 함유하는화장료 조성물
KR101545552B1 (ko) 황금 붉은덕다리버섯 발효액을 유효성분으로 함유하는 피부 미백용 화장료 조성물
US20020041908A1 (en) Iridacea extracts for stimulating the immune system
KR20180108255A (ko) 파리신 비를 포함하는 화장료 조성물
JPH11171722A (ja) 皮膚外用剤
KR101521240B1 (ko) 황금 붉은덕다리버섯 발효액을 유효성분으로 함유하는 피부 염증 및 아토피 개선용 화장료 조성물
AU2009238172B2 (en) Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof
KR100613266B1 (ko) 각질 박리 촉진제 및 이를 유효 성분으로 함유하는 의약품 또는 화장료
KR20160081163A (ko) 컴파운드 k 및 이카리시드 b2를 함유하는 피부 보습 또는 미백용 외용제 조성물
KR101305411B1 (ko) 참바늘버섯 균사체 추출물을 함유하는 피부 외용제 조성물
KR20000050304A (ko) 안정화시킨 비타민 ｃ와 알파-히드록시 액시드(ａｈａ)를 함유하는 피부보호 화장료 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase